Revolution Medicines (RVMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 18, 2026, at 7:30 a.m. PDT via virtual platform.
Proxy materials, including the Notice, Proxy Statement, and Annual Report, are available online for review and voting.
Proxies may be submitted via internet, phone, or mail, with instructions provided for each method.
Voting matters and shareholder proposals
Election of two Class I directors to serve until the 2029 Annual Meeting or until successors are elected.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation (Say-on-Pay) as disclosed in the Proxy Statement.
Proxies are authorized to transact other business as may properly come before the meeting.
Board of directors and corporate governance
Director nominees for election are Alexis Borisy and Mark A. Goldsmith, MD, Ph.D.
Board of Directors recommends voting FOR all proposals presented.
Latest events from Revolution Medicines
- Daraxonrasib delivers landmark survival in PDAC as late-stage RAS inhibitor pipeline advances.RVMD
Corporate presentation - FDA accepted daraxonrasib NDA; net loss rose to $644M, cash reserves reached $3.9B.RVMD
Q2 2026 - Daraxonrasib doubled survival and improved quality of life in metastatic pancreatic cancer.RVMD
Study result - Daraxonrasib achieved a 60% reduction in risk of death in metastatic pancreatic cancer.RVMD
Corporate presentation - Daraxonrasib's Phase 3 success in pancreatic cancer drives global expansion and strong financials.RVMD
Q1 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, all board-recommended.RVMD
Proxy filing - RASolute 302 trial readout and broad RAS-targeted strategies mark key upcoming milestones.RVMD
TD Cowen 46th Annual Health Care Conference - Secured $2 billion flexible funding to drive global RAS(ON) inhibitor launches and trials.RVMD
Investor Update - RAS(ON) inhibitors show strong efficacy and safety in PDAC, NSCLC, and CRC, enabling phase III trials.RVMD
Status Update